Tyra Biosciences Advances TYRA-300 Bladder Cancer Trial: What Investors Should Watch

Tyra Bioscience, Inc (TYRA) announced an update on their ongoing clinical study.

The Phase 2 study “A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)” aims to test if TYRA-300 can safely shrink or control tumors in a defined group of bladder cancer patients. This update matters because it moves Tyra Biosciences, Inc closer to proof that its precision bladder cancer pill may offer a new option in a market still dominated by surgery and local treatments.

The trial tests TYRA-300, an oral pill designed to target FGFR3 changes seen in certain low grade bladder cancers. The goal is to offer a focused treatment that patients can take at home while reducing the need for repeated procedures and hospital visits.

The study is interventional and randomized, which means patients are assigned by chance to different dose groups of TYRA-300. It uses a parallel design with no blinding, so all participants and investigators know which dose is being used, and the main goal is to measure how well the drug treats cancer while tracking side effects.

Cohort A receives 60 mg once daily, while Cohort B receives 50 mg once daily, and a possible Cohort C may open if data suggest another dose should be explored. This structure lets Tyra quickly compare dose levels and adjust its strategy without restarting the trial, which can speed decisions that matter for investors and regulators.

The study was first submitted on April 25, 2025, signaling Tyra’s move from early development into a more advanced testing phase. The last update was filed on February 11, 2026, which shows the company is actively refining the protocol as new information comes in.

The trial is currently listed as recruiting, meaning patient enrollment is underway but no final results are available yet. The primary and estimated completion dates have not been publicly detailed, but investors should treat the current period as an execution phase where enrollment speed and early safety signals will shape expectations for value inflection milestones.

For TYRA, positive progress in SURF302 could support a higher valuation by validating its FGFR3 strategy in non muscle invasive bladder cancer, a segment with recurring disease and high unmet need. Any signs of strong efficacy or clean safety could drive buying interest, as investors often reward small caps when a focused asset shows differentiation against standard surgery and intravesical therapies.

In the broader sector, this trial puts TYRA in the mix with other companies pursuing FGFR targeted drugs and next generation bladder cancer treatments. While larger oncology players and existing FGFR drugs set a competitive bar, a well tolerated, oral option tailored to low grade, intermediate risk patients could carve out a niche and improve Tyra’s negotiating position for future partnerships or licensing deals.

The study remains ongoing and recently updated, and investors can find further details, including future timeline changes and outcome updates, on the ClinicalTrials.gov portal.

To learn more about TYRA’s potential, visit the Tyra Bioscience, Inc drug pipeline page.